Medeor Therapeutics

Founded in 2012 and headquartered in South San Francisco, US, Medeor Therapeutics specializes in cellular immunotherapy to improve kidney transplant success. The company was established through a combination of research from Stanford University and innovative approaches in the transplant field. Currently, Giovanni Ferrara serves as CEO.Medeor Therapeutics specializes in innovative cellular immunotherapy aimed at improving outcomes for kidney transplant recipients. The company’s core offering is a breakthrough therapy that utilizes mixed chimerism, allowing for the co-existence of donor and recipient immune cells, thereby promoting prolonged organ survival without the continuous need for immunosuppressant drugs. This technology platform, which originated from research at Stanford University over two decades ago, has advanced through a pivotal Phase 3 clinical trial targeting HLA-matched living donor kidney-transplant recipients. The end use case addresses significant challenges in the transplant community, including the rejection rates that range from 30-50% within ten years post-transplant.Information regarding Medeor Therapeutics' revenue structure is not publicly disclosed. However, the company operates within a clinical trial framework that likely involves partnerships with healthcare institutions and hospitals to facilitate its Phase 3 studies and potential future product launches. Revenue generation is anticipated to be derived from the successful commercialization of its flagship immunotherapy, which is expected to involve direct sales to healthcare facilities and possibly collaborations with larger pharmaceutical companies for distribution. As the company moves towards filing for biologics license approval (BLA), its revenue model may evolve to include subscription or partnership arrangements with healthcare systems for the provision of its therapies.Medeor Therapeutics plans to enhance its product offerings with new therapies targeting additional transplant scenarios, although specific release dates have yet to be disclosed. The company aims to expand its services into new markets across Europe and Asia by 2025, enhancing the reach of its innovative immunotherapy solutions.80 mn will support these initiatives, enabling further clinical research and potential partnerships in these regions. Additionally, the company is exploring potential collaborations with larger pharmaceutical firms to strengthen its market presence and expedite product availability.

1. Series B

   Nov 27, 2017

   Amount

   $57M

   Investors

   Locked